EQT is happy to announce that Isabel De Paoli, former Chief Strategy Officer at leading science and technology company Merck KGaA, will join as a Partner in the Private Equity advisory team. Isabel joins in September 2021, will be based in Munich and will join EQT’s global healthcare sector team.

Isabel brings extensive experience in the healthcare industry. Most recently, she was with Merck KGaA where she was responsible in her role as Chief Strategy Officer for developing and executing on global transformation and corporate projects, including long-term portfolio strategy, business strategies and corporate technology ventures. At Merck KGaA, Isabel successfully built a corporate science and tech ventures fund and captive new business ventures investing in groundbreaking new technologies. She has a degree in Chemical Engineering from Universidade Estadual de Campinas and a Master of Science in Process Engineering with focus on Bioprocess from the Technical University Hamburg-Harburg.

“We are thrilled to welcome Isabel to EQT. She possesses a broad range of business development and strategy experience and a strong investment and value creation track record in the healthcare sector. We look forward to collaborating with Isabel across the entire Private Capital platform,” said Michael Bauer, Co-Head of EQT’s Global Healthcare Sector Team.

“Isabel’s pharma and life sciences industry expertise makes her a perfect addition to the team, and we look forward to further building our deep healthcare sector expertise with her support,” said Johannes Reichel, Partner and Head of Private Equity Germany at EQT.

“Teaming up with EQT will give me an even broader platform and perspective, especially given the focus on creating positive impact with each investment across the board. Investing in and developing the healthcare industry, in all shape and form, is a great opportunity to make life better for so many. I can’t wait to join this high-energy team and become part of EQT’s entrepreneurial culture,” said Isabel De Paoli.

EQT is one of the most active healthcare investors globally, with approximately EUR 39 billion invested across 20 investments since 2016. Recent activities in the sector include the IPO of Certara, EQT’s first U.S. IPO, the acquisition of Recipharm, a leading global CDMO servicing the pharmaceutical industry, and the acquisition of the leading dermatology company, Galderma (formerly known as Nestlé Skin Health), the largest private equity healthcare deal in the last ten years in Europe.

Categories: People

About the Author